Abstract
Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with isolated mutations/mutation groups were wild-type for all other genes tested (NPM1, IDH1/2, N/KRAS, FLT3-ITD, and TP53) except for the gene of interest. Reported p-values utilized the cox model Wald test.